Trovafloxacine mesylate, a new fluoroquinolone, was launched in
Switzerland and the US, in both oral (Trovan) and iv (alatrofloxacin, N-Ala-Ala
substituted prodrug of trovafloxacin) formulations for adult use as broadspectrum antibiotic agent in diverse acute bacterial infections, particularly
community-acquired respiratory infections (ie nocosomial pneumonia). In a
clinical study of acute exacerbations of chronic bronchitis, trovafloxacin at 100 or
200 mg daily demonstrated advantages over amoxicillin, cephalosporins and
clarithromycin. A favorable pharmacokinetic profile allows only once a day dosing.
